Search Within

Gary Schwartz

  1. "Gastrointestinal Oncology Service"
Formats
  1. Journal Article (55)
  2. Meeting Abstract (42)
  3. Book Section (1)
  4. Conference Paper (1)
Groups
  1. Department of Medicine (99)
  2. Gastrointestinal Oncology Service (99)
  3. Solid Tumor Oncology Division (99)
  4. Center for Pancreatic Cancer Research (88)
  5. Biostatistics Service (24)
  6. Epidemiology and Biostatistics (24)

More Groups

People
  1. David Kelsen (79)
  2. Eileen O'Reilly (36)
  3. Leonard Saltz (30)
  4. Manish Shah (26)
  5. David Ilson (23)
  6. Nancy Kemeny (17)

More People

Years
  1. 2013 (4)
  2. 2012 (4)
  3. 2011 (1)
  4. 2010 (2)
  5. 2009 (3)
  6. 2008 (4)

More Years

Publications
  1. Journal of Clinical Oncology (29)
  2. Clinical Cancer Research (12)
  3. Cancer (9)
  4. Annals of Oncology (6)
  5. Proceedings of the American Association for Cancer Research Annual Meeting (6)
  6. Annals of Surgical Oncology (4)

More Publications

Publishers
  1. American Society of Clinical Oncology (29)
  2. American Association for Cancer Research (18)
  3. Springer (11)
  4. Oxford University Press (10)
  5. Wiley Blackwell (10)
  6. Elsevier Inc. (7)

More Publishers

Results (99)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Prognostic factors (PF) in advanced hepatocellular carcinoma (AHCC): Multivariate analysis and comparison between staging systems (SS) in patients (pts) treated at Memorial Sloan-Kettering Cancer Center (MSKCC)
    Meeting Abstract

    Huitzil, F. D.; Capanu, M.; Jacobs, G.; Smith, W.; O'Reilly, E.; Shah, M.; Schwartz, G. K.; Saltz, L. B.; Kelsen, D. P.; Abou-Alfa, G. K.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors
    Journal Article

    Fornier, M. N.; Rathkopf, D.; Shah, M.; Patil, S.; O'reilly, E.; Tse, A. N.; Hudis, C.; Lefkowitz, R.; Kelsen, D. P.; Schwartz, G. K.
    Clinical Cancer Research (2007)

    Fulltext@MSK | Save
  • Final results of a multicenter phase II study of irinotecan (CPT), cisplatin (CIS), and bevacizumab (BEV) in patients with metastatic gastric or gastroesophageal (GEJ) adenocarcinoma (NCI #6447)
    Meeting Abstract

    Shah, M. A.; Ramanathan, R. K.; Ilson, D.; Randazzo, J.; Schwartz, G. K.; Tse, A.; D'adamo, D.; Levner, A.; Capanu, M.; Kelsen, D. P.
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • Randomized phase II trial comparing two paclitaxel (P))-cisplatin (C) containing chemoradiation (CRT) regimens as adjuvant therapy in resected gastric cancer (RTOG 0114)
    Meeting Abstract

    Schwartz, G. K.; Winter, K.; Minsky, B.; Janjan, N.; Schaefer, P.; Thomson, J.; Anne, R.; Gross, H.; Willet, C.; Kelsen, D.
    International Journal of Radiation Oncology, Biology, Physics (2006)

    Fulltext@MSK | Save
  • A non-randomized phase II study of sequential irinotecan (CPT) and flavopiridol (F) in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Meeting Abstract

    Abou-Alfa, G. K.; Carvajal, R. D.; Chung, K. Y.; Ghossein, R. A.; Capanu, M.; Gonen, M.; Jacobs, G.; Kelsen, D. P.; Schwartz, G. K.
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinorna
    Journal Article

    Shah, M. A.; Ramanathan, R. K.; Ilson, D. H.; Levnor, A.; D'adamo, D.; O'reilly, E.; Tse, A.; Trocola, R.; Schwartz, L.; Capanu, M.; more...
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • Measuring tumor response and shape change on CT: Esophageal cancer as a paradigm
    Journal Article

    Schwartz, L. H.; Colville, J. A. C.; Ginsberg, M. S.; Wang, L.; Mazumdar, M.; Kalaigian, J.; Hricak, H.; Ilson, D.; Schwartz, G. K.
    Annals of Oncology (2006)

    Fulltext@MSK | Save
  • A multicenter phase II study of irinotecan (CPT), cisplatin (CIS), and bevacizumab (BEV) in patients with unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
    Meeting Abstract

    Shah, M. A.; Ilson, D.; Ramanathan, R. K.; Levner, A.; D'adamo, D.; Schwartz, L.; Casper, E.; Schwartz, G. K.; Kelsen, D. P.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • A randomized phase II trial comparing two paclitaxel (P)-cisplatin (C) containing chemoradiation (CRT) regimens as adjuvant therapy in resected gastric cancer (RTOG Intergroup #0114)
    Meeting Abstract

    Schwartz, G. K.; Winter, K.; Minsky, B.; Janjan, N.; Schaefer, P.; Thomson, J.; Rani, A.; Gross, H.; Willett, C.; Kelsen, D.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • A phase I clinical and pharmacokinetic study of weekly docetaxel followed by flavopiridol: Promising activity in metastatic pancreatic cancer
    Meeting Abstract

    Rathkopf, D.; Fornier, M.; Shah, M. A.; Kortmansky, J.; O'reilly, E.; Winkelmann, J.; Balzano, L.; Kelsen, D. P.; Schwartz, G. K.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save